Cogent Biosciences Stock Working Capital

COGT Stock  USD 7.54  0.55  7.87%   
Cogent Biosciences fundamentals help investors to digest information that contributes to Cogent Biosciences' financial success or failures. It also enables traders to predict the movement of Cogent Stock. The fundamental analysis module provides a way to measure Cogent Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cogent Biosciences stock.
Last ReportedProjected for Next Year
Net Working Capital240.8 M173.7 M
Change In Working Capital11.6 M12.2 M
Change In Working Capital is likely to gain to about 12.2 M in 2025, whereas Net Working Capital is likely to drop slightly above 173.7 M in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cogent Biosciences Company Working Capital Analysis

Cogent Biosciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Cogent Biosciences Working Capital

    
  240.76 M  
Most of Cogent Biosciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cogent Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cogent Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Cogent Biosciences is extremely important. It helps to project a fair market value of Cogent Stock properly, considering its historical fundamentals such as Working Capital. Since Cogent Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cogent Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cogent Biosciences' interrelated accounts and indicators.
0.990.52-0.57-0.830.730.710.741.00.350.820.930.980.920.99-0.280.87
0.990.46-0.65-0.790.680.650.661.00.420.790.930.990.940.97-0.360.82
0.520.460.07-0.830.850.830.720.5-0.020.810.50.470.450.56-0.120.65
-0.57-0.650.070.24-0.040.090.09-0.62-0.8-0.25-0.56-0.68-0.77-0.480.77-0.14
-0.83-0.79-0.830.24-0.97-0.9-0.82-0.81-0.11-0.99-0.79-0.8-0.77-0.880.23-0.89
0.730.680.85-0.04-0.970.950.840.7-0.070.970.710.680.610.8-0.110.88
0.710.650.830.09-0.90.950.890.67-0.20.90.650.630.520.770.10.88
0.740.660.720.09-0.820.840.890.7-0.190.80.620.630.530.80.260.94
1.01.00.5-0.62-0.810.70.670.70.390.810.920.990.940.98-0.330.84
0.350.42-0.02-0.8-0.11-0.07-0.2-0.190.390.160.510.480.510.29-0.660.02
0.820.790.81-0.25-0.990.970.90.80.810.160.830.80.750.87-0.230.89
0.930.930.5-0.56-0.790.710.650.620.920.510.830.940.850.92-0.320.79
0.980.990.47-0.68-0.80.680.630.630.990.480.80.940.960.96-0.40.8
0.920.940.45-0.77-0.770.610.520.530.940.510.750.850.960.89-0.530.69
0.990.970.56-0.48-0.880.80.770.80.980.290.870.920.960.89-0.230.93
-0.28-0.36-0.120.770.23-0.110.10.26-0.33-0.66-0.23-0.32-0.4-0.53-0.230.04
0.870.820.65-0.14-0.890.880.880.940.840.020.890.790.80.690.930.04
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

Cogent Net Invested Capital

Net Invested Capital

114 Million

At this time, Cogent Biosciences' Net Invested Capital is comparatively stable compared to the past year.
In accordance with the company's disclosures, Cogent Biosciences has a Working Capital of 240.76 M. This is 43.44% lower than that of the Biotechnology sector and 55.3% lower than that of the Health Care industry. The working capital for all United States stocks is 83.71% higher than that of the company.

Cogent Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cogent Biosciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cogent Biosciences could also be used in its relative valuation, which is a method of valuing Cogent Biosciences by comparing valuation metrics of similar companies.
240.8M914.8M643.6M561.4M100%
Cogent Biosciences is currently under evaluation in working capital category among its peers.

Cogent Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cogent Biosciences from analyzing Cogent Biosciences' financial statements. These drivers represent accounts that assess Cogent Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cogent Biosciences' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap21.9M124.4M332.3M679.0M611.1M641.7M
Enterprise Value(9.4M)(112.5M)115.8M558.8M502.9M528.1M

Cogent Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cogent Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cogent Biosciences' managers, analysts, and investors.
56.4%
Environmental
Governance
Social

Cogent Fundamentals

Return On Equity-1.0
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%1,000%
Return On Asset-0.54
Current Valuation604.92 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%0%100%200%
Shares Outstanding113.85 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%800%
Shares Owned By Insiders0.15 %
Shares Owned By Institutions99.84 %
Number Of Shares Shorted10.8 M
Price To Earning(5.03) X
Price To Book5.24 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%
Price To Sales1,321 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Gross Profit(121.63 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%0%200%400%600%
EBITDA(275.94 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Net Income(255.86 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%3,500%
Cash And Equivalents325.56 M
Cash Per Share4.95 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%40%
Total Debt17.47 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%
Debt To Equity0.09 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Current Ratio11.96 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%0%20%40%
Book Value Per Share1.32 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%
Cash Flow From Operations(207.79 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,200%-1,000%-800%-600%-400%-200%
Short Ratio6.99 X
Earnings Per Share(1.94) X
Price To Earnings To Growth(0.14) X
Target Price16.4
Beta0.031
Market Capitalization795.81 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%150%
Total Asset327.9 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%50%100%150%200%250%300%
Retained Earnings(859.48 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%
Working Capital240.76 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset37.62 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%200%250%300%
Current Liabilities21.06 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31100%200%300%400%500%
Net Asset327.9 M

About Cogent Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cogent Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cogent Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cogent Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.